Melissa was healthy, had no worrisome symptoms, and never expected cancer to become part of her story. But after making the Galleri multi-cancer early detection (MCED) test part of her health routine, her second annual test returned a Cancer Signal Detected result with a predicted origin of liver/bile ducts.

On this episode of The Cancer SIGNAL podcast, Melissa shares what happened next, including the diagnostic journey that would confirm her Stage IA cancer diagnosis.

Melissa also reflects on the role her family played throughout treatment and recovery, and why her experience has strengthened her commitment to proactive health and early detection.

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

See Important Safety Information: https://www.galleri.com/safety-information

Host Rayshawnda Madison connects with Roger, a returning guest who first shared his story in 2023 after receiving a Cancer Signal Detected result from the Galleri multi-cancer early detection (MCED) test. Follow-up testing led to a stage II pancreatic cancer diagnosis.

Now, three years later, Roger reflects on how life has evolved since completing treatment, what survivorship looks like for him today, and the mindset that helped him move forward. He also shares how the experience changed his relationship with health, why he remains vigilant, and what motivates him to continue raising awareness about MCED testing.

The overall sensitivity in study participants with pancreas cancer was 83.7%. (61.9% for stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV).

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

See Important Safety Information: https://www.galleri.com/safety-information

In this episode, Robert, a carpenter from the Midlands in England and a participant in the NHS-Galleri trial, joins host Shawnda Madison to share his experience.

After enrolling in the trial, Robert received a Cancer Signal Detected result from the Galleri multi-cancer early detection (MCED) test despite having no symptoms. The initial diagnostic evaluation did not identify cancer, but a subsequent Galleri test the following year returned the same result, leading his care team to continue investigating.

Eventually, a biopsy revealed a small HPV-related cancer at the base of his tongue. Robert reflects on the uncertainty of waiting for answers, the treatment and recovery that followed, and how the experience changed the way he thinks about health, screening, and the value of finding cancer earlier.

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

See Important Safety Information: https://www.galleri.com/safety-information

The overall sensitivity in study participants with head and neck cancer was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV).

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

Kevin McFarland, a lieutenant with his local fire department, and Dr. Robert Merritt, a thoracic surgeon who helped diagnose and treat Kevin, share how the Galleri multi-cancer early detection (MCED) test unexpectedly revealed that Kevin had a signal for esophageal cancer—despite having no symptoms. The test, offered by the fire department where Kevin works, led to further medical exams that identified his specific type of cancer. Kevin reflects on the emotional, mental, and physical impact of his diagnosis and treatment, the importance of early detection, and how the experience renewed his appreciation for his health and family and gave him "a new lease on life." Dr. Merritt credits the Galleri test and early detection for Kevin's positive prognosis and recovery. Their story highlights the critical role of accessibility, awareness, and advocacy in cancer detection.

Watch the full episode on YouTube: https://www.youtube.com/watch?v=BVOJXdWUkCo

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

See Important Safety Information: http://bit.ly/33m8pFa

The overall sensitivity in study participants with esophageal cancer was 85.0% (12.5% for stage I, 64.7% stage II, 94.1% stage III, 100% stage IV).

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

In this episode of The Cancer SIGNAL, Nima Nabavizadeh, MD, an associate professor of radiation medicine at Oregon Health & Science University (OHSU) and the chief medical officer at the Cancer Early Detection Advanced Research Center (CEDAR) at OHSU, joins host Susanna Quinn to share the results from the groundbreaking GRAIL PATHFINDER 2 clinical trial unveiled at the European Society for Medical Oncology (ESMO 2025) Congress. As the principal investigator for the trial, which examined the safety and performance of the Galleri multi-cancer early detection test, Dr. Nabavizadeh discusses why the findings are pivotal for patients and could potentially redefine early cancer detection.

Watch the full episode on YouTube: https://youtu.be/owhDC8vH1hw

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

See Important Safety Information: http://bit.ly/33m8pFa

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

In this episode of The Cancer SIGNAL, Tad Carper, Senior VP of Communications for the Dallas Cowboys, shares how a multi-cancer early detection (MCED) screening unexpectedly revealed a cancer signal for head and neck cancer—despite experiencing no symptoms. The test, sponsored for the team's assistant coaches by quarterback Dak Prescott's foundation, Faith Fight Finish, was the first step toward Tad's stage two cancer diagnosis. Tad reflects on the emotional and mental impact of his diagnosis, the importance of early detection, and how the experience reshaped his values—deepening his appreciation for life, relationships, and the power of proactive health care. His story highlights the critical role of accessibility, awareness, and advocacy in cancer detection, and his commitment to "paying it forward" by helping others take early action in their own health journeys.

Watch the full episode on YouTube: https://www.youtube.com/watch?v=WuManHvHtS4

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider–recommended screening tests.

See Important Safety Information: http://bit.ly/33m8pFa

The overall sensitivity in study participants with head and neck cancer was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV).

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

At a semiannual primary care visit, Jack's doctor mentioned multi-cancer early detection (MCED) testing. Though Jack wasn't experiencing symptoms, and has no family history of cancer, he decided to take the test. Two Cancer Signal Detected results from MCED screening tests taken six months apart helped his care team determine the necessary diagnostics that confirmed an early-stage cancer diagnosis. Listen to Jack's story to learn more about the impact early cancer detection had on his life.

Watch the full episode on YouTube: https://youtu.be/p8fFVshFWJk

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

See Important Safety Information: http://bit.ly/33m8pFa

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

Dr. Patrick McGill was instrumental in introducing Community Health Network to multi-cancer early detection (MCED) testing and integrating it into routine screenings offered to patients. Dr. McGill is Executive Vice President and Chief Transformation Officer at Community Health Network, and as a practicing primary care physician he believes strongly in the importance of catching cancer as early as possible to improve outcomes for patients. In this episode he shares how MCED has made an impact at Community Health Network.

Watch the full episode on YouTube: https://youtu.be/X9PyQeiO0HM

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN

Transcripts: https://grail.com/podcast/

Sign up for GRAIL's newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Rx only. See Important Safety Information: http://bit.ly/33m8pFa

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.